Cancer, not HPV vaccination, hastened death of UK girl

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

Cancer killed a 14-year-old girl who died shortly after being given Cervarix as part of a national immunization program. Early reports speculated that there may have been a link between the shot and her death, but according to a coroner’s assessment, there was no indication that the culprit was the HPV vaccine, which is marketed by GlaxoSmithKline. The girl’s death was caused by malignant disease in the heart and lungs, according to the coroner’s report.

Cancer killed a 14-year-old girl who died shortly after being given Cervarix as part of a national immunization program. Early reports speculated that there may have been a link between the shot and her death, but according to a coroner's assessment, there was no indication that the culprit was the HPV vaccine, which is marketed by GlaxoSmithKline. The girl's death was caused by malignant disease in the heart and lungs, according to the coroner's report.

Nevertheless, the UK immunization program was suspended. Other girls who received Cervarix complained of dizziness and nausea but they did not require hospitalization for their symptoms.

GlaxoSmithKline recalled the batch of vaccine that included the dose administered to the deceased girl. The company's plan to launch Cervarix as a competitor to Merck's Gardasil in the U.S. was recently delayed after the FDA requested more time to review the application.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content